Related Experiment Video
Updated: Jul 2, 2026
06:38
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Adjuvant therapy for renal cell carcinoma.
1Abramson Cancer Center, 12 Penn Tower, 3400 Spruce Street, Philadelphia, PA 19104, USA. naomi.haas@uphs.upenn.edu
Current Oncology Reports
|September 4, 2008
Summary
Adjuvant therapy for high-risk renal cell carcinoma (RCC) is being re-evaluated. New agents approved for metastatic RCC offer hope for improving outcomes after surgery in localized kidney cancer.
Area of Science:
- Oncology
- Nephrology
- Surgical Oncology
Background:
- Localized renal cell carcinoma (RCC) management is primarily surgical.
- High-risk RCC recurrence post-resection leads to metastatic disease and poor survival.
- Past adjuvant therapies have failed to improve outcomes in RCC.
Purpose of the Study:
- To review the rationale for novel adjuvant therapies in high-risk RCC.
- To discuss ongoing adjuvant clinical trials for kidney cancer.
- To consider future directions for adjuvant therapy development.
Main Methods:
- Review of current literature on adjuvant therapy for RCC.
- Analysis of FDA-approved agents for metastatic RCC.
- Examination of ongoing and proposed adjuvant clinical trials.
Main Results:
- Recent FDA approvals for metastatic RCC agents have spurred interest in adjuvant settings.
- Several novel agents are being investigated for adjuvant use in high-risk RCC.
- Understanding the rationale and trial landscape is crucial for advancing adjuvant therapy.
Conclusions:
- Adjuvant therapy holds promise for improving survival in high-risk RCC patients.
- Novel agents and ongoing trials represent a significant shift in managing localized kidney cancer.
- Strategic development of future trials is essential for optimizing adjuvant treatment efficacy.
More Related Videos
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:11Renal Failure: Dose Adjustments
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...